 NASHUA, N.H., April 23, 2020 GLOBE NEWSWIRE -- iCAD, Inc. iCAD ICAD today announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500 shares of the Companys common stock at 8.00 per share, pursuant to a registered direct offering. The Company intends to use the net proceeds for working capital and for other general corporate purposes, including for the conduct of post-market studies for the Companys Xoft intra-operative radiation therapy IORT for glioblastoma and other brain cancers. This offering is being made pursuant to an effective shelf registration statement on Form S-3 File No. 333-235887 previously filed with the U.S. Securities and Exchange Commission the SEC and made effective on January 31, 2020. 